<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We measured the presence of antibodies to the Epstein-Barr virus (EBV) nuclear antigen 2B (EBNA2B) in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> and related disorders, persons with human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, persons at risk for <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e>, and <z:mpath ids='MPATH_458'>normal</z:mpath> persons </plain></SENT>
<SENT sid="1" pm="."><plain>Sera from 38% (16 of 43) of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> and 35% (43 of 123) of HIV-positive individuals reacted with EBNA2B, versus 25% (21 of 83) of the high-risk patients and 7.5% (5 of 65) of the <z:mpath ids='MPATH_458'>normal</z:mpath> persons </plain></SENT>
<SENT sid="2" pm="."><plain>Screening these sera against cell lines that express EBNA2B, EBNA2A, or neither antigen revealed that only a proportion of these sera contained EBNA2B-specific antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Many sera reacted with both antigens </plain></SENT>
<SENT sid="4" pm="."><plain>Of the EBNA2B-specific sera, 14% (6 of 43) were from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>, 16% (20 of 123) from HIV-positive individuals, 5% (4 of 83) from high-risk individuals, and 4.5% (3 of 65) from <z:mpath ids='MPATH_458'>normal</z:mpath> persons </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of antibodies to the EBNA2B in HIV-infected individuals indicates that they may be infected with type B strains of EBV </plain></SENT>
</text></document>